PU-AD

Drug Profile

PU-AD

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samus Therapeutics
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries

Most Recent Events

  • 30 Mar 2017 Preclinical trials in Alzheimer's disease and Brain injuries in USA
  • 30 Mar 2017 Samus Therapeutics plans to files an IND application for Alzheimer's disease
  • 30 Mar 2017 Samus Therapeutics plans a phase I trial for Brain injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top